NASDAQ: MLYS Mineralys Therapeutics, Inc. 8-K

Mineralys pays $200M to eliminate lorundrostat royalties, secures $500M debt facility

Filed June 3, 2026 · Period ending June 2, 2026 · ~1 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade MLYS commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 3, 2026 3:12 PM